Pulmonx Q3 2025 Earnings Report

Pulmonx EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.40
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Pulmonx Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $20.78 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Pulmonx Announcement Details

• Quarter: Q3 2025
• Date: 10/29/2025
• Time: Before Market Opens
• Conference Call Date: Wednesday, October 29, 2025
• Conference Call Time: 4:30PM ET

Pulmonx (NASDAQ:LUNG) is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.

The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe. Pulmonx supports its commercial portfolio with comprehensive physician training programs, ongoing clinical research collaborations, and robust post-market surveillance initiatives. These efforts help validate long-term safety and efficacy, while also guiding future enhancements and potential label expansions for its technologies.

Headquartered in Redwood City, California, Pulmonx maintains an international presence through offices and distribution partners in Europe. Under the leadership of President and Chief Executive Officer Antonio Pizarro, the company continues to advance its mission of improving the quality of life for patients with obstructive lung diseases. Pulmonx remains committed to innovation in minimally invasive therapies and to building strategic relationships with physicians and healthcare institutions worldwide.